© 2008 The Royal College of Psychiatrists
EDITORIALS |
CATIE and CUtLASS: can we handle the truth?
Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
Department of Psychiatry, College of Physicians and Surgeons, Columbia University and New York State Psychiatric Institute, and Lieber Center for Schizophrenia Research, and New York Presbyterian Hospital and Columbia University Medical Center, New York, USA
Correspondence: Professor Shôn Lewis, University of Manchester University Place (3rd floor east), Stopford Building, Oxford Road, Manchester M13 9PL, UK. Email: shon.lewis{at}manchester.ac.uk
S.L. is the Chief Investigator of the CUtLASS study and J.L. is the Chief Investigator of the CATIE study. S.L. has received honoraria from several pharmaceutical companies. J.L. has received research funding from several pharmaceutical companies.
Shôn Lewis (pictured) is Head of the Psychiatry Research Group at the University of Manchester. His research interests focus on risk factors and interventions in early psychosis. Jeffrey Lieberman is Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and Director of the New York State Psychiatric Institute. His research has centred on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders.
Two large, non-commercial clinical trials comparing first- and second-generation antipsychotic drugs for people with chronic schizophrenia in the US and UK have shown unexpected results. In general, the newer drugs were no more effective or better tolerated than the older drugs. Clozapine outperformed other second-generation drugs. The implications are considered.
 View larger version (131K): [in a new window] [as a PowerPoint slide] |
Related articles in BJP:
- From The Editor's Desk
- Peter Tyrer
BJP 2008 192: 242.[Full Text] - Highlights of this issue
- Sukhwinder S. Shergill
BJP 2008 192: A10.[Full Text]
This article has been cited by other articles:
 |
|
 |
|
  D. O. Meltzer, A. Basu, and H. Y. Meltzer Comparative Effectiveness Research For Antipsychotic Medications: How Much Is Enough? Health Aff., September 1, 2009; 28(5): w794 - w808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E Dean Personalized Medicine: Boon or Budget-Buster? Ann. Pharmacother., May 1, 2009; 43(5): 958 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al. Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection Pharmacol. Rev., September 1, 2008; 60(3): 358 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Scott Cognitive-behavioural therapy for severe mental disorders: back to the future? The British Journal of Psychiatry, June 1, 2008; 192(6): 401 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shuchman MD and P. C. Hebert MD MHSc Bringing a research base to psychiatry Can. Med. Assoc. J., May 6, 2008; 178(10): 1257 - 1258. [Full Text] [PDF]
|
|
|
|
|
|
M. Shuchman MD and P. C. Hebert MD MHSc Etablir une base de recherche en psychiatrie Can. Med. Assoc. J., May 6, 2008; 178(10): 1259 - 1260. [Full Text] [PDF]
|
|
eLetters:
Read all eLetters
- Some Issues with Cutlass
- Mark Agius, et al.
- BJP Online, 17 Mar 2008 [Full text]
- The truth about sulpiride?
- Philip J Cowen
- BJP Online, 9 Apr 2008 [Full text]
- Handling the Truth?
- Richard E Hodgson
- BJP Online, 18 Jun 2008 [Full text]